Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › MA › Marlborough › NPI 1952347791
Lab

Quest Diagnostics LLC

Quest Diagnostics LLC was paid $209.74M by Medicaid between Jan 2018 and Dec 2024, across 421 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 16% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS LLC
MARLBOROUGH, MA 01752
33aNPI1952347791assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$209.74M
24GClaims45,938,450
24DCodes billed421
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Massachusetts

Rank by total paid#1 of 63
Median peer was paid$473K
This provider vs. median444×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20185,614,562$21.32M
20195,998,339$22.74M
20205,287,200$25.74M
20218,033,818$38.58M
20226,632,039$34.06M
20237,742,164$34.95M
2024incomplete6,630,328$32.35M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 16% 1,204,524 683,750 $33.04M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 14% 577,385 446,990 $30.13M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 9.1% 950,705 553,557 $19.18M
81513 3.4% 82,909 77,648 $7.07M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2.8% 522,089 474,149 $5.96M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2.8% 521,951 473,997 $5.96M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2.5% 526,494 492,546 $5.29M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 2.5% 519,853 486,690 $5.23M
86480 2.1% 134,364 126,179 $4.47M
84443 Thyroid stimulating hormone (TSH) 2.0% 1,084,291 1,008,072 $4.16M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.9% 90,625 84,449 $4.02M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.8% 200,840 184,638 $3.70M
409 more codes
83036 Hemoglobin; glycosylated (A1C) 1.6% 866,443 $3.26M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.3% 1,310,635 $2.63M
86003 1.2% 57,555 $2.53M
86803 1.1% 401,876 $2.31M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.1% 118,978 $2.22M
36415 Collection of venous blood by venipuncture 1.0% 2,375,818 $2.15M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.0% 152,904 $2.12M
83013 <1% 57,995 $2.02M
82607 <1% 342,851 $1.71M
87086 Culture, bacterial; quantitative colony count, urine <1% 376,535 $1.52M
86780 <1% 220,394 $1.45M
87522 Neg quan hep c or qual rna <1% 57,950 $1.36M
83718 <1% 1,057,543 $1.33M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 11,106 $1.18M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 56,908 $1.17M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 2,051 $1.15M
82465 <1% 1,069,582 $1.10M
84478 <1% 1,055,544 $1.09M
84439 <1% 259,863 $1.08M
87340 <1% 240,774 $1.04M
87070 <1% 217,122 $1.03M
82728 <1% 290,729 $974K
82746 <1% 222,503 $944K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 3,439 $811K
85027 <1% 383,506 $776K
87536 <1% 25,613 $758K
86235 <1% 27,064 $742K
87088 <1% 290,269 $739K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 28,427 $724K
80061 Lipid panel <1% 131,613 $700K
80050 General health panel <1% 36,044 $681K
84153 <1% 119,373 $666K
81001 <1% 410,750 $661K
83655 <1% 148,535 $645K
86769 <1% 16,377 $619K
83550 <1% 270,790 $609K
80053 Comprehensive metabolic panel <1% 154,932 $596K
83540 <1% 295,312 $518K
82565 <1% 1,533,961 $504K
87186 <1% 119,642 $493K
84702 <1% 68,438 $470K
87631 <1% 6,131 $459K
86317 <1% 78,469 $455K
83970 <1% 47,480 $447K
86704 <1% 76,949 $443K
84450 <1% 1,436,398 $437K
86705 <1% 71,637 $437K
82310 <1% 1,503,281 $425K
82043 <1% 171,751 $425K
86709 <1% 73,019 $416K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 4,647 $416K
86618 <1% 66,714 $415K
87077 <1% 139,766 $413K
82947 <1% 1,519,576 $405K
84460 <1% 1,441,147 $405K
84295 <1% 1,497,633 $404K
86592 <1% 200,801 $403K
88142 <1% 34,374 $401K
87480 <1% 35,864 $393K
87510 <1% 35,859 $391K
82374 <1% 1,496,126 $390K
84520 <1% 1,518,788 $388K
84132 <1% 1,498,943 $383K
86038 <1% 100,724 $375K
82670 <1% 31,641 $375K
87660 <1% 35,839 $374K
82435 <1% 1,496,142 $373K
86140 <1% 145,682 $370K
84075 <1% 1,385,760 $365K
82247 <1% 1,383,163 $363K
82105 <1% 46,113 $362K
82040 <1% 1,405,419 $359K
82784 <1% 68,553 $353K
86617 <1% 25,825 $346K
82570 <1% 265,566 $341K
86706 <1% 65,620 $338K
86708 <1% 59,651 $336K
87081 <1% 87,602 $326K
83525 <1% 58,861 $325K
83516 <1% 37,028 $322K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 9,053 $308K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 7,972 $305K
84146 <1% 50,529 $296K
84155 <1% 1,389,689 $286K
83001 <1% 44,889 $284K
86376 <1% 46,118 $276K
87902 <1% 2,934 $272K
83735 <1% 101,035 $267K
86666 <1% 19,841 $266K
86762 <1% 64,558 $262K
88112 <1% 11,149 $254K
82785 <1% 38,612 $240K
85652 <1% 176,836 $239K
84481 <1% 45,775 $235K
84403 <1% 25,034 $232K
86800 <1% 38,749 $228K
83002 <1% 36,788 $224K
86364 <1% 28,745 $223K
86008 <1% 10,110 $218K
86787 <1% 48,155 $216K
80081 <1% 4,599 $215K
86200 <1% 38,586 $203K
86665 <1% 15,510 $200K
84480 <1% 44,299 $186K
83020 <1% 20,660 $184K
87147 <1% 47,197 $177K
86696 <1% 34,203 $171K
82627 <1% 24,712 $169K
86160 <1% 16,139 $163K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 3,334 $162K
84436 <1% 65,867 $159K
86765 <1% 39,079 $159K
83880 <1% 13,123 $156K
86735 <1% 36,820 $152K
86360 <1% 11,471 $148K
82533 <1% 20,881 $148K
83690 <1% 46,847 $147K
86431 <1% 59,588 $136K
85610 <1% 71,582 $135K
88141 <1% 15,906 $134K
82274 <1% 19,500 $132K
80074 <1% 5,764 $130K
86753 <1% 14,597 $129K
83021 <1% 14,107 $128K
80164 <1% 22,814 $126K
87517 <1% 5,360 $123K
86039 <1% 27,282 $119K
82550 <1% 37,443 $119K
86225 <1% 22,887 $118K
81401 <1% 852 $112K
86695 <1% 31,131 $112K
80197 <1% 20,696 $111K
83721 <1% 29,723 $110K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 3,784 $109K
84144 <1% 12,715 $107K
88304 <1% 7,794 $107K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 1,414 $106K
84479 <1% 42,891 $106K
87506 <1% 933 $106K
86361 <1% 9,846 $104K
85730 <1% 36,752 $102K
84703 <1% 25,888 $102K
82330 <1% 20,606 $102K
88342 <1% 3,102 $102K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 2,253 $97K
86141 <1% 15,526 $95K
84270 <1% 11,684 $94K
83014 <1% 22,568 $93K
80048 Basic metabolic panel (calcium, ionized) <1% 27,950 $92K
86850 <1% 35,964 $91K
87338 <1% 11,579 $90K
82248 <1% 158,730 $89K
82150 <1% 26,834 $89K
87209 <1% 15,664 $88K
84550 <1% 63,851 $88K
86334 <1% 9,912 $86K
87427 <1% 14,170 $85K
87799 <1% 5,804 $84K
86258 <1% 7,302 $82K
87625 <1% 4,810 $81K
87449 <1% 16,281 $78K
86664 <1% 13,442 $78K
85018 <1% 96,058 $77K
88341 <1% 1,679 $77K
82950 <1% 33,267 $76K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 305 $76K
82652 <1% 3,573 $75K
87045 <1% 14,886 $74K
84154 <1% 18,840 $73K
84165 <1% 17,602 $73K
87329 <1% 12,419 $72K
80178 <1% 21,612 $69K
85014 <1% 83,176 $67K
84156 <1% 41,334 $66K
84681 <1% 9,014 $66K
82977 <1% 35,106 $65K
84466 <1% 10,134 $64K
84402 <1% 4,021 $63K
86901 <1% 39,379 $63K
86900 <1% 39,484 $62K
87493 <1% 3,558 $61K
84100 <1% 78,183 $61K
81003 <1% 54,556 $60K
87205 <1% 25,206 $59K
87075 <1% 11,316 $59K
87177 <1% 15,665 $59K
85007 <1% 39,546 $59K
83520 <1% 8,907 $59K
86747 <1% 5,135 $58K
86147 <1% 5,093 $58K
88185 <1% 238 $56K
82024 <1% 5,242 $56K
83615 <1% 30,526 $55K
87324 <1% 10,193 $53K
86870 <1% 2,276 $53K
81329 <1% 1,424 $50K
82951 <1% 8,060 $50K
83090 <1% 8,258 $49K
80076 <1% 10,472 $48K
86021 <1% 5,024 $48K
87150 <1% 2,296 $45K
85045 <1% 21,005 $44K
87254 <1% 5,506 $42K
88230 <1% 930 $40K
82378 <1% 5,584 $39K
85041 <1% 38,548 $39K
81596 <1% 1,404 $37K
87497 <1% 2,011 $37K
82390 <1% 7,517 $37K
86304 <1% 3,842 $35K
86777 <1% 4,891 $35K
87046 <1% 10,659 $35K
84134 <1% 8,656 $35K
87102 <1% 6,313 $35K
86644 <1% 5,045 $34K
81025 <1% 9,760 $34K
87650 <1% 2,695 $33K
86255 <1% 5,880 $32K
88262 <1% 662 $32K
85379 <1% 6,227 $32K
82747 <1% 5,596 $32K
83521 <1% 3,549 $31K
84425 <1% 3,109 $31K
87255 <1% 2,887 $28K
88344 <1% 506 $28K
82677 <1% 2,314 $26K
85048 <1% 25,061 $26K
86778 <1% 3,457 $25K
88300 <1% 3,794 $25K
85060 <1% 3,673 $25K
80055 <1% 828 $24K
87101 <1% 4,753 $24K
82787 <1% 2,070 $24K
86593 <1% 11,318 $23K
86308 <1% 7,933 $23K
86645 <1% 4,365 $23K
86301 <1% 3,052 $23K
84166 <1% 3,094 $23K
87106 <1% 4,290 $22K
87484 <1% 1,561 $22K
82103 <1% 4,737 $21K
86060 <1% 5,689 $21K
83010 <1% 3,706 $21K
84432 <1% 3,863 $21K
86359 <1% 3,950 $21K
82668 <1% 2,093 $19K
87206 <1% 5,599 $19K
86702 <1% 2,695 $19K
86381 <1% 2,546 $17K
86336 <1% 2,306 $17K
87469 <1% 2,173 $16K
80156 <1% 3,050 $16K
85660 <1% 5,845 $16K
85246 <1% 1,658 $15K
87468 <1% 1,658 $15K
87040 <1% 2,660 $15K
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 19,970 $14K
86036 <1% 1,980 $14K
86663 <1% 2,588 $14K
85613 <1% 2,874 $14K
86015 <1% 2,616 $14K
88312 <1% 497 $13K
81015 <1% 8,715 $13K
82952 <1% 6,357 $13K
80185 <1% 2,322 $12K
86335 <1% 1,317 $12K
86701 <1% 2,695 $12K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,039 $12K
87350 <1% 1,971 $12K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 184 $12K
83921 <1% 1,494 $12K
86707 <1% 1,767 $11K
87512 <1% 1,779 $11K
87140 <1% 2,756 $11K
ATP03 <1% 2,427 $10K
85245 <1% 1,230 $10K
ATP14 <1% 6,231 $10K
84630 <1% 1,432 $10K
84484 <1% 1,807 $9K
ATP17 <1% 4,671 $9K
84207 <1% 713 $9K
87220 <1% 2,729 $8K
80159 <1% 1,488 $8K
80051 <1% 2,279 $8K
87076 <1% 1,591 $7K
85240 <1% 925 $7K
83883 <1% 1,653 $7K
83935 <1% 2,158 $7K
86300 <1% 1,026 $7K
80069 <1% 1,921 $7K
80202 <1% 1,079 $7K
ATP15 <1% 2,437 $7K
85004 <1% 4,527 $7K
82232 <1% 992 $7K
83498 <1% 308 $6K
87275 <1% 902 $6K
82525 <1% 806 $6K
87276 <1% 902 $6K
83930 <1% 2,078 $6K
87328 <1% 924 $6K
87481 <1% 480 $6K
87529 <1% 526 $6K
88189 <1% 182 $6K
81511 <1% 788 $6K
87107 <1% 807 $5K
84445 <1% 168 $5K
84300 <1% 2,274 $5K
87272 <1% 843 $5K
88184 <1% 250 $5K
88271 <1% 79 $5K
80158 <1% 763 $5K
86886 <1% 1,663 $5K
88307 <1% 78 $5K
82340 <1% 1,901 $5K
86146 <1% 256 $5K
82542 <1% 343 $5K
88313 <1% 121 $4K
85384 <1% 919 $4K
84255 <1% 215 $4K
82140 <1% 558 $4K
87207 <1% 1,147 $4K
ATP16 <1% 1,209 $4K
85306 <1% 451 $4K
80195 <1% 624 $4K
ATP09 <1% 2,452 $3K
ATP08 <1% 2,205 $3K
80184 <1% 786 $3K
85300 <1% 557 $3K
82672 <1% 194 $3K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 291 $3K
81229 <1% 92 $3K
83003 <1% 483 $3K
89055 <1% 1,263 $3K
86341 <1% 84 $3K
85303 <1% 375 $2K
82985 <1% 679 $2K
80177 <1% 513 $2K
87800 <1% 32 $2K
87478 <1% 335 $2K
80299 <1% 273 $2K
85049 <1% 2,140 $2K
84482 <1% 208 $2K
87300 <1% 222 $2K
82553 <1% 438 $2K
87280 <1% 253 $2K
87015 <1% 487 $2K
86880 <1% 567 $2K
86256 <1% 245 $1K
84305 <1% 113 $1K
88235 <1% 15 $1K
82172 <1% 338 $1K
82610 <1% 298 $1K
83993 <1% 129 $1K
80175 <1% 283 $1K
80162 <1% 240 $1K
86628 <1% 55 $1K
ATP04 <1% 236 $1K
ATP07 <1% 448 $963.73
86812 <1% 79 $907.14
83695 <1% 110 $829.88
ATP02 <1% 359 $818.42
81243 <1% 16 $785.02
86611 <1% 56 $783.84
80165 <1% 3,263 $694.36
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 450 $660.92
83519 <1% 96 $644.97
84590 <1% 114 $635.65
87563 <1% 39 $624.89
82104 <1% 71 $572.70
87185 <1% 454 $509.24
89060 <1% 124 $495.40
89051 <1% 168 $490.17
86905 <1% 194 $479.22
ATP11 <1% 198 $464.72
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 2,165 $464.51
ATP10 <1% 146 $379.39
85597 <1% 58 $368.39
86337 <1% 30 $365.30
82530 <1% 28 $351.99
ATP05 <1% 86 $350.07
81256 <1% 245 $340.42
82088 <1% 12 $335.51
87116 <1% 68 $334.43
ATP18 <1% 148 $320.61
81241 <1% 763 $269.39
87172 <1% 92 $264.69
81240 <1% 417 $178.50
82575 <1% 25 $144.00
88302 <1% 14 $141.48
87260 <1% 13 $122.99
83835 <1% 13 $111.87
86037 <1% 14 $111.85
81291 <1% 565 $111.74
82552 <1% 13 $85.35
84133 <1% 42 $85.05
99001 <1% 154 $83.64
80183 <1% 14 $77.43
86632 <1% 13 $72.97
84560 <1% 27 $70.91
85598 <1% 12 $60.36
ATP13 <1% 13 $55.20
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 363 $46.35
36416 <1% 378 $35.00
80349 0% 130 $0.00
80358 0% 268 $0.00
G0475 Hiv antigen/antibody, combination assay, screening 0% 274 $0.00
G0434 Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter 0% 426 $0.00
80354 0% 322 $0.00
80348 0% 46 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOWLES, CHARLES (SR. VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under BOWLES, CHARLES

Full network →
ProviderLocationPaid
Quest Diagnostics of Pennsylvania, INC.Pittsburgh, PA$132.39M
Quest Diagnostics Clinical Laboratories INCSeattle, WA$109.23M
Quest Diagnostics Clinical Laboratories INCPortland, OR$21.85M
Quest Diagnostics of Pennsylvania INC.Buffalo, NY$20.20M
Quest Diagnostics Clinical Laboratories INCCollegeville, PA$12.52M
Solstas Lab Partners Group LLCGreensboro, NC$11.62M
Quest Diagnostics Incorporated MiFlint, MI$8.64M
Quest Diagnostics Clinical Laboratories INCTucker, GA$3.66M
Unilab CorporationWest Hills, CA$3.12M
Quest Diagnostics of Pennsylvania INC.Twinsburg, OH$2.56M
Quest Diagnostics Incorporated MDFalls Church, VA$936K
Quest Diagnostics LLCWallingford, CT$706K
Quest Diagnostics of Pennsylvania INC.North Syracuse, NY$492K
Solstas Lab Partners, LLCKnoxville, TN$455K
Quest Diagnostics Clinical Laboratories INCNorristown, PA$319K
Unilab CorporationSan Jose, CA$253K
Unilab CorporationOrange, CA$122K
Quest Diagnostics LLCStratford, CT$103K
Unilab CorporationBakersfield, CA$53K
Quest Diagnostics Clinical Laboratories INCHorsham, PA$48K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.